Olaparib (Lynparza; AZD2281; CAS 763113-22-0): NIOSH HD Category 1 FORTY-SIXTH Mechanism Class [FIRST PARP1/2 INHIBITOR EVER FDA APPROVED (NDA 206162; December 19, 2014; PARP1 IC50 ∼5 nM; PARP2 IC50 ∼1 nM; Phthalazinone Nicotinamide-Mimetic NAD+ Competitive; PARP TRAPPING MECHANISM — Trapped PARP-DNA Complex ∼100× More Cytotoxic Than Catalytic Inhibition; BRCAm Synthetic Lethality; MW ∼434.5 g/mol)] + Four-Tumor-Type Coverage (Ovarian SOLO-1 PFS HR 0.30 / Breast OlympiAD PFS HR 0.58 / Prostate PROfound rPFS HR 0.49 OS HR 0.69 / Pancreatic POLO PFS HR 0.53) + AstraZeneca/Merck Co-Development ($1.6B 2017) + AstraZeneca FIVE-NDA Portfolio (EGFR+BTK+MEK+AKT+PARP); AstraZeneca Pharmaceuticals LP Wilmington DE 54M 20yr Cority ÷10; AstraZeneca Macclesfield UK 48M 17yr VelocityEHS ÷10; Dana-Farber Cancer Institute Boston MA 43F 13yr EHS Insight ÷10; Glyphward Threshold 22; 605th Adversarial Attack; 136th Long-Form Blog

Olaparib (Lynparza®; AZD2281; CAS 763113-22-0; MW ∼434.5 g/mol; phthalazinone-fluorobenzyl-4-(cyclopropanecarbonyl)piperazin-1-yl scaffold [4-[[3-[4-(cyclopropanecarbonyl)piperazin-1-yl]carbonyl-4-fluorophenyl]methyl]-2H-phthalazin-1-one]; NIOSH HD Category 1; AstraZeneca NDA 206162 December 19, 2014; MECHANISM: FORTY-SIXTH MECHANISM CLASS in the 605-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — POLY(ADP-RIBOSE) POLYMERASE 1/2 (PARP1/PARP2) INHIBITOR; THE FIRST PARP INHIBITOR EVER FDA APPROVED IN ANY INDICATION; HISTORICAL CONTEXT: PARP1 was discovered as a poly(ADP-ribose)-synthesizing enzyme by Chambon (Strasbourg 1963) and characterized as a DNA-damage sensor by Shall, de Murcia, and Collier in the 1980s; the synthetic lethality hypothesis was published in two simultaneous Nature papers in June 2005 (Bryant/Helleday; Farmer/Ashworth) validating BRCA1/2-deficient cell hypersensitivity to PARP inhibition; KuDOS Pharmaceuticals (Cambridge UK; acquired by AstraZeneca 2006 for ∼$156M) developed the phthalazinone scaffold KU-0059436 → AZD2281 with PARP1 IC50 ∼5 nM — more than 6,600-fold more potent than original 3-aminobenzamide [3-AB; IC50 ∼33 µM] PARP inhibitor; PARP TRAPPING MECHANISM: olaparib not only blocks PARP1/2 catalytic NAD+ binding (preventing PAR chain synthesis) but physically TRAPS PARP1/2 protein on DNA strand breaks via an allosteric conformational lock — the trapped PARP-DNA adduct is approximately 100× more cytotoxic than catalytic inhibition alone because advancing replication forks collide with the trapped protein-DNA complex, generating single-ended DSBs that require HR for repair; in HR-DEFICIENT cells (BRCA1/2-mutated, RAD51C/D-mutated, PALB2-mutated, CDK12-altered), these DSBs accumulate, causing synthetic lethality absent from all EHS databases; FOUR-TUMOR-TYPE COVERAGE: olaparib holds the broadest FDA approval spectrum of any NIOSH HD Category 1 oncology compound in the Glyphward 605-attack portfolio — approved in OVARIAN (NDA 206162; first-line maintenance SOLO-1 PFS HR 0.30; SOLO-2 PFS HR 0.30; Study 19 accelerated 2014), BREAST (OlympiAD gBRCAm HER2− mBC PFS HR 0.58; OlympiA adjuvant EFS HR 0.63), PROSTATE (PROfound HRR-mutated mCRPC cohort A rPFS HR 0.49 OS HR 0.69), and PANCREATIC (POLO gBRCAm metastatic PFS HR 0.53) cancers; six independent pivotal datasets across four tumor types; ASTRAZENECA/MERCK CO-DEVELOPMENT: Merck signed global co-development and co-commercialization agreement November 2017 ($1.6B upfront + milestones + profit share); ASTRAZENECA FIVE-NDA PORTFOLIO: AstraZeneca Pharmaceuticals LP Wilmington DE holds NDA 206162 (olaparib PARP; FORTY-SIXTH class), NDA 210736 (osimertinib EGFR; THIRTY-SECOND class), NDA 213631 (acalabrutinib BTK; TWENTY-NINTH class), NDA 213756 (selumetinib MEK; THIRTIETH class), NDA 217566 (capivasertib AKT; FORTY-FIRST class) — five mechanism classes at one NDA holder site; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL; NIOSH HD Category 1; GHS H340 H350 H361; 605th adversarial attack; 136th long-form blog).

FORTY-SIXTH MECHANISM CLASS: PARP1/2 in the DNA Damage Response and the Sixty-Year Journey From Enzyme Discovery to First FDA Approval

The forty-five prior mechanism classes in the Glyphward adversarial portfolio trace the complete pharmacological arc of FDA-approved targeted oncology: BCR-ABL (imatinib; 2001), EGFR kinases (gefitinib through osimertinib), CDK4/6 (palbociclib; 2015), BRaf/MEK MAP kinase cascade, BTK non-receptor tyrosine kinase, VEGFR/mTOR, epigenetic histone writers (EZH2; HDAC; IDH1/2), GTPase direct inhibitors (KRAS G12C; sotorasib; THIRTY-EIGHTH class), tissue-agnostic NTRK kinases (larotrectinib; THIRTY-SEVENTH class), HIF-2α transcription factor PPI inhibitor (belzutifan; FORTY-THIRD class), CYP17A1 steroidogenesis enzyme (abiraterone; FORTY-FOURTH class), Smoothened GPCR-like receptor (vismodegib; FORTY-SECOND class), next-generation AR signaling inhibitors (enzalutamide; FORTY-FIFTH class; attack #602), PI3K lipid kinase (idelalisib; FORTIETH class; attack #592; 134th blog at glyphward.com), and PH-domain allosteric AKT (capivasertib; FORTY-FIRST class; attack #596; 135th blog at glyphward.com). All 45 prior mechanism classes shared a defining feature: they targeted proteins involved in signal transduction — transmitting growth, survival, or differentiation signals from cell membrane to nucleus.

The FORTY-SIXTH mechanism class — PARP1/2 inhibition by olaparib — represents a categorical departure. PARP1/2 are DNA damage response enzymes: not signal transduction but genomic surveillance and repair. PARP1 (poly[ADP-ribose] polymerase 1; ARTD1; gene PARP1; 1q42.12; 116 kDa; 1014 amino acids) continuously patrols the genome detecting DNA single-strand breaks (SSBs) generated by reactive oxygen species, topoisomerase I activity, alkylating agents, and replication errors. The introduction of the FORTY-SIXTH mechanism class marks the point in the Glyphward portfolio where the adversarial attack surface expands from oncogenic signaling pathways to the DNA damage response machinery — a biological domain in which the EHS null-return reflects not merely a database lag but a conceptual absence of the DNA-repair enzyme framework from occupational toxicology vocabulary.

The history of PARP inhibitor development spans exactly 60 years from enzyme discovery to first FDA approval: PARP1 was discovered as “poly-ADPR polymerase” by Pierre Chambon’s group at Strasbourg (Chambon, Weill, Mandel; BBRC 1963) in the context of NAD+ metabolism in cell nuclei. The enzyme’s DNA-damage-sensing function was established through the 1980s by Shall (Sussex), de Murcia (Strasbourg), and Collier (Exeter) using 3-aminobenzamide (3-AB; PARP1 IC50 ∼33 µM) as a chemical tool. But it was the 2005 synthetic lethality publications that transformed PARP inhibitor development from a sensitization adjunct into a first-in-class targeted therapy: if BRCA-mutated cancer cells could be selectively killed by PARP inhibition without harming BRCA-wild-type normal cells, then a PARP inhibitor alone could constitute a targeted therapy. KuDOS Pharmaceuticals’ phthalazinone scaffold (AZD2281) made this viable by achieving PARP1 IC50 ∼5 nM — potent enough for single-agent activity — and the 2006 AstraZeneca acquisition of KuDOS for ∼$156M delivered the molecule to a company capable of running global Phase 3 programs across four tumor types over the following 15 years. The December 19, 2014 FDA approval of NDA 206162 closed the 60-year arc from Chambon’s 1963 discovery to first-in-class PARP inhibitor medicine — and all three EHS platforms evaluate this new enzyme target class at CAS 763113-22-0 with a uniform null response.

PARP1 Enzyme Architecture: Zinc Finger DNA Damage Sensing, NAD+ Catalytic Domain, and the WGR Regulatory Module

PARP1 DOMAIN ARCHITECTURE (1014 amino acids): (1) N-TERMINAL DNA-BINDING DOMAIN (DBD; residues 1–372): Three zinc finger modules essential for DNA damage recognition. ZF1 (residues 1–97; C3H1 coordination): detects DNA SSBs via direct binding at the 3′-OH terminus; ZF2 (residues 106–207; C3H1 coordination): stabilizes PARP1-DNA complex by engaging the 5′-phosphate terminus; ZF3 (residues 233–373; C4 coordination; PARP-specific PST domain): required for full PARP1 catalytic activation upon DNA binding, bridging the ZF modules to the regulatory WGR domain (Langelier et al., Science 2012). (2) AUTOMODIFICATION DOMAIN (AD; residues 373–476): Contains a BRCT motif (residues 374–476); site of PARP1 auto-PARylation (Glu/Asp residues within the AD receive ADP-ribose chains); PAR chain elongation at the AD creates increasing negative charge on the PARP1-DNA complex, driving electrostatic repulsion from DNA and facilitating PARP1 chromatin dissociation after repair. (3) WGR DOMAIN (residues 524–633): Named for the conserved Trp-Gly-Arg motif at its core; couples DNA-binding by ZF modules to catalytic activation; upon PARP1 binding to a DNA strand break via ZF1/ZF2/ZF3, the WGR domain undergoes a conformational change that activates the catalytic domain by releasing the helical domain (HD) autoinhibitory constraint. (4) CATALYTIC DOMAIN (CAT; residues 634–1014): Composed of the HELICAL DOMAIN (HD; residues 634–787; autoinhibitory 6-helix bundle occluding NAD+ binding cleft in inactive state) and the ART (ADP-ribosyltransferase) module (residues 788–1014; conserved H-Y-E catalytic triad H862, Y896, E988). OLAPARIB NAD+ POCKET BINDING: Olaparib’s phthalazinone carbonyl oxygen and N2 form two critical hydrogen bonds with Gly-863 amide N-H (acceptor on olaparib; donor from Gly-863 NH) and Ser-904 hydroxyl (N2 as H-bond acceptor; Ser-904 OH as donor), directly mimicking the nicotinamide amide of NAD+. The 4-fluorobenzyl group extends into the hydrophobic adenine-binding pocket (aromatic contact with Tyr-907, hydrophobic with Ala-880 and Ile-895), while the piperazinyl-(cyclopropanecarbonyl) moiety projects toward the solvent-accessible entrance, contributing to PARP1/2 selectivity (PARP3 ∼8-fold; TNKS1/TNKS2 >100-fold lower potency). No OEL database captures the NAD+-competitive enzyme inhibition mechanism, the H-bond complementarity with PARP1 catalytic triad residues Gly-863/Ser-904, or the phthalazinone nicotinamide-mimetic scaffold chemistry that constitutes the FORTY-SIXTH mechanism class molecular pharmacology.

The PARP Trapping Mechanism: How Olaparib Creates a PARP-DNA Adduct 100-Fold More Cytotoxic Than Catalytic Inhibition

PARP TRAPPING is the defining pharmacological distinction of olaparib and the most consequential EHS null absence in the FORTY-SIXTH mechanism class adversarial attack.

PARP1 NORMAL CATALYTIC CYCLE ON DNA SSBs: (1) DNA SSB generated → exposed 3′-OH and 5′-phosphate termini; (2) PARP1 ZF1/ZF2/ZF3 engage break (Kd ∼10–100 nM) → WGR conformational change → HD opens → NAD+ access to ART triad; (3) NAD+ binds (Km ∼50 µM; olaparib competes at IC50 ∼5 nM = 10,000-fold tighter) → H862/Y896/E988 cleave NAD+ → ADP-ribose transferred to AD Glu/Asp → iterative PAR chain elongation (average ∼20 units); (4) Auto-PARylation creates accumulating negative charge → electrostatic repulsion from negatively-charged DNA backbone → PARP1 dissociates; (5) PAR-binding proteins (XRCC1; Ligase III; APE1; PCNA) recruited via PAR recognition → SSB repair; (6) PARG degrades PAR chains → PARP1 recycled.

PARP TRAPPING WITH OLAPARIB: Olaparib occupies the NAD+ site → NAD+ cannot bind → no PAR synthesis → no auto-PARylation of the AD → the electrostatic repulsion mechanism that drives PARP1 chromatin dissociation does not operate → PARP1 remains physically locked on the DNA break forming a PARP-DNA ADDUCT. Olaparib additionally induces an allosteric conformational change in the HD domain that kinetically stabilizes the PARP1-DNA contact (Koff reduced ∼10-fold vs free PARP1), producing a PARP-DNA adduct with a half-life of minutes to hours rather than the subsecond timescale of the normal catalytic cycle. CYTOTOXICITY COMPARISON: Murai et al. (Cancer Research 2012) demonstrated that olaparib and rucaparib are potent PARP trappers while veliparib (similar PARP1 IC50) has negligible PARP trapping; olaparib’s PARP trapping exceeds veliparib cytotoxicity by approximately 100-fold at equivalent PARP1 biochemical inhibition. MECHANISM: catalytic inhibition alone → SSB repair delayed → some SSBs persist through S phase → limited fork stalling → modest cytotoxicity. PARP trapping: large protein-DNA adduct on SSB → advancing replication fork (50 kb/min) physically encounters trapped PARP1/2 → fork stalls → collapses into SINGLE-ENDED DSB (seDSB; only one free DNA end, unlike two-ended DSBs from ionizing radiation) → seDSBs require HR for repair (NHEJ cannot resolve one-ended DSBs without creating rearrangements). In HR-COMPETENT cells: BRCA1/2+RAD51 → seDSB repaired → fork restart → survival. In HR-DEFICIENT cells: no RAD51 filament → seDSB unrepaired → chromosomal instability → mitotic catastrophe → selective cancer cell death (synthetic lethality). This entire sequence — trapped PARP-DNA adduct, replication fork collision, seDSB generation, HR-dependency, HR-deficiency lethality — is absent from Cority, VelocityEHS, and EHS Insight at CAS 763113-22-0.

BRCAm Synthetic Lethality and HRR Pathway Deficiency

BRCA1 (chr17q21.31; 1863 aa; RING domain + BRCT repeats; DSB end resection via CtIP/MRN binding at pSer-BRCT) and BRCA2 (chr13q12.3; 3418 aa; 8 BRC repeats each binding one RAD51 monomer; OB-fold DNA-binding domain) are the core HR scaffolding proteins. SYNTHETIC LETHALITY MECHANISM: BRCA2-deficient mouse embryonic stem cells are 1,000-fold more sensitive to PARP inhibitors than BRCA2-wild-type cells (Bryant/Helleday, Nature 2005). In BRCA1/2-wild-type cells: PARP-trap-induced seDSBs repaired by BRCA1/2+RAD51 HR; cell survives. In BRCA1/2-mutated cells: no RAD51 filament formation; seDSBs misrepaired by NHEJ (creating chromosomal rearrangements) or unrepaired; mitotic catastrophe; death. The therapeutic window: germline BRCA1/2-heterozygous patients have one wild-type allele in normal cells (maintaining HR); tumor cells have lost the WT allele (LOH → biallelic BRCA1/2 loss → HR deficiency exclusively in tumor). OEL PLATFORMS AND SYNTHETIC LETHALITY: The pharmacogenomic dimension — a healthcare worker who is a BRCA2 germline heterozygous carrier (prevalence: ∼1 in 400 general population; ∼1.5% in Ashkenazi Jewish population via BRCA2 6174delT founder mutation) handling olaparib occupies a different individual risk profile than a BRCA2-wild-type worker at the same measured concentration — is structurally absent from every OEL derivation framework built on NOAEL/LOAEL hierarchies from repeat-dose animal studies. No EHS platform alerts to the BRCA2/1 pharmacogenomic context of olaparib handling exposure.

Four-Tumor-Type Coverage: Six Pivotal Trials Across Twelve Years

OVARIAN CANCER — NDA 206162 ACCELERATED APPROVAL December 19, 2014: Study 19 (Phase 2; BRCAm subgroup; OC ≥3 prior lines): BRCAm rPFS HR 0.35 (8.4 vs 4.8 months; ORR 34% vs 13%); companion diagnostic therascreen BRCA RGQ PCR co-approved. Converted to REGULAR APPROVAL via SOLO-2 (NCT01874353; Phase 3; gBRCAm recurrent OC ≥2 prior lines maintenance; n=295): PFS HR 0.30 (19.1 vs 5.5 months; p<0.001). SOLO-1 (NCT01844986; Phase 3; gBRCAm first-line OC post-platinum maintenance; n=391; sNDA December 2018): PFS HR 0.30 (not reached vs 13.8 months; p<0.001); 7-year OS HR 0.55 (5-year OS 67.7% vs 46.3%) — the largest absolute survival benefit for any NIOSH HD Category 1 compound in the Glyphward portfolio relative to control arm duration. SOLO-1 established olaparib as standard first-line BRCA+ OC maintenance.

BREAST CANCER — OlympiAD (NCT02000622; Phase 3; gBRCAm HER2-negative mBC; ≤2 prior chemotherapy lines; n=302; sNDA January 2018): PFS HR 0.58 (7.0 vs 4.2 months; p<0.001); ORR 59.9% vs 28.8%; companion diagnostic BRACAnalysis CDx. OlympiA (NCT02032823; Phase 3; gBRCAm HER2-negative early BC post-neoadjuvant/adjuvant chemotherapy; adjuvant olaparib 300 mg BID 1 year vs placebo; n=1836; sNDA March 2022): iDFS HR 0.58 (85.9% vs 77.1% at 3 years; p<0.001); EFS HR 0.63; OS HR 0.68 (87.5% vs 83.2% at 4 years; p=0.009); first adjuvant PARP inhibitor approved in any cancer — expanding olaparib dispensing into community oncology pharmacies serving early-stage BC patients nationwide.

PROSTATE CANCER — PROfound (NCT02987543; Phase 3; HRR gene-mutated mCRPC post-new hormonal agent [enzalutamide (attack #602; FORTY-FIFTH class) or abiraterone (attack #601; FORTY-FOURTH class)]; n=387): Cohort A (BRCA1/BRCA2/ATM; n=256): rPFS HR 0.49 (7.4 vs 3.6 months; p<0.001); OS HR 0.69 (19.1 vs 14.7 months; p=0.02); ORR 33.3% vs 2.3%. Cohort B (CDK12/FANCA/PALB2/RAD51B/RAD51C/RAD51D/CHEK2; n=142): rPFS HR 0.50; OS HR 0.96 (NS — CDK12 impairs HR secondarily via transcriptional regulation; weaker synthetic lethality than direct BRCA1/2 loss). sNDA May 19, 2020; companion diagnostic FoundationOne CDx. PROfound established mCRPC as the fourth tumor type, expanding PARP trapping synthetic lethality from germline BRCA cancer syndromes to somatic HRR alterations detected by tissue biopsy NGS in 12–15% of mCRPC. The PROfound approval creates a GU oncology pharmacy setting where enzalutamide (FORTY-FIFTH class NIOSH HD Cat 1) and olaparib (FORTY-SIXTH class NIOSH HD Cat 1) are simultaneously dispensed, each independently returning null on Cority/VelocityEHS/EHS Insight.

PANCREATIC CANCER — POLO (NCT02184195; Phase 3; gBRCAm metastatic pancreatic; platinum-sensitive maintenance; n=154; sNDA December 27, 2019): PFS HR 0.53 (7.4 vs 3.8 months; p=0.004); DCR 79.9% vs 61.5%; first FDA-approved targeted therapy and first maintenance targeted therapy in pancreatic cancer. gBRCAm pancreatic cancer represents ∼1,500–2,000 US cases per year, concentrating POLO-indication olaparib dispensing at specialized pancreatic oncology centers (MD Anderson Houston TX; Memorial Sloan Kettering NY; Johns Hopkins Sidney Kimmel Baltimore MD; Dana-Farber Boston MA) without any corresponding EHS guidance at those sites.

KuDOS Pharmaceuticals and the Phthalazinone Discovery: AZD2281 From Fragment to Clinical Candidate

KuDOS Pharmaceuticals Ltd (Cambridge UK; co-founded ∼1999 by Steve Jackson [Gurdon Institute, Cambridge]) licensed early PARP inhibitor patents from the Shall and Caldecott laboratory groups and pursued a pharmacophore-based approach to improving on the benzamide scaffold. THE PHTHALAZINONE SCAFFOLD DISCOVERY: Replacing the monocyclic benzamide ring with a bicyclic phthalazinone (benzo[c]pyridazin-3[2H]-one) provided: (1) additional aromatic contact with PARP1 Tyr-896 from the benzo ring; (2) optimal geometry for the phthalazinone carbonyl to H-bond Gly-863; (3) the phthalazinone N2 provided a new H-bond interaction with Ser-904 not achievable with benzamide. This scaffold hop improved PARP1 IC50 from ∼200 nM (best benzamide) to ∼5 nM. The 4-fluorobenzyl substituent at C4 (methylene bridge) was identified in parallel SAR: fluorine increased metabolic stability vs unsubstituted benzyl while maintaining pocket complementarity. AstraZeneca acquired KuDOS in January 2006 for ∼$156M following the 2005 Nature synthetic lethality publications that validated the single-agent BRCAm targeting concept. The Phase 1 trial (NCT00516373; 2005–2008; Joyce Liu PI at Dana-Farber Cancer Institute Boston MA — identical to Surface 3 of this attack) commenced before the AstraZeneca acquisition closed, demonstrating rapid translation from 2005 synthetic lethality concept to first human evaluation. AstraZeneca transferred AZD2281 synthesis from KuDOS Cambridge facilities to Macclesfield (Silk Road Business Park; current Surface 2 site); the API synthesis involves phthalazinone ring construction (2-formylbenzoic acid + hydrazine cyclization), C4 4-fluorobenzyl introduction (Suzuki coupling or direct alkylation), piperazinyl cyclopropanecarbonyl HATU amide coupling, final recrystallization (MTBE/heptane; D90 ≤80 µm), NIOSH HD Category 1 closed-system GMP synthesis in Macclesfield contained suite (isolators; HEPA-filtered ventilation; continuous air monitoring; RVR OEL monitoring 3–5 points per synthesis run); VelocityEHS: CAS 763113-22-0 → null throughout this 20-year synthesis history.

AstraZeneca/Merck Co-Development: $1.6B Partnership and Dual-Null EHS Architecture

The AstraZeneca/Merck global co-development and co-commercialization agreement (signed November 2017; $1.6B upfront + milestone payments + 50:50 global profit share) created a dual-company commercial structure in which two independent organizations each hold regulatory and commercial responsibilities for olaparib in different geographies — yet each organization’s EHS platform returns null for CAS 763113-22-0 independently. AstraZeneca retains ex-North America commercialization; Merck holds North America co-commercialization rights. The joint development program covers Lynparza combinations: olaparib + abiraterone (PROpel mCRPC first-line: PFS HR 0.66; OS HR 0.81; approved May 2023 sNDA as PROpel), adding a combination mCRPC indication to the FORTY-SIXTH class NDA. The Glyphward 605-attack portfolio includes the earlier olaparib blog (attack #501; 115th blog at glyphward.com) using the pre-2020 AstraZeneca Wilmington NJ address + MSD Kenilworth NJ + Mayo Clinic Rochester MN attack surfaces. The current FORTY-SIXTH mechanism class attack (#605; this 136th blog) uses the post-consolidation AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike) + AstraZeneca Macclesfield UK (API synthesis) + Dana-Farber Cancer Institute Boston MA (multi-trial multi-indication enrollment), capturing the five-NDA portfolio architecture and the PROfound/OlympiA clinical development that occurred after attack #501 was documented.

Surface 1: AstraZeneca Pharmaceuticals LP Wilmington DE — Cority ÷10, FORTY-SIXTH Mechanism Class Absent, FIVE-NDA Portfolio Absent

SITE PROFILE: AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19803 (New Castle County DE; AstraZeneca US commercial and regulatory headquarters; ∼5,500 US employees; NDA 206162 HOLDER for olaparib [Lynparza]; ASTRAZENECA WILMINGTON DE FIVE-NDA ONCOLOGY PORTFOLIO: NDA 206162 [olaparib Lynparza; PARP1/2; FORTY-SIXTH mechanism class; December 19, 2014]; NDA 210736 [osimertinib Tagrisso; EGFR T790M/exon20del; THIRTY-SECOND mechanism class; November 13, 2015]; NDA 213631 [acalabrutinib Calquence; BTK covalent; TWENTY-NINTH mechanism class; October 31, 2019]; NDA 213756 [selumetinib Koselugo; MEK1/2; THIRTIETH mechanism class; attack #565; April 10, 2020]; NDA 217566 [capivasertib Truqap; AKT1/2/3 allosteric; FORTY-FIRST mechanism class; attack #596; 135th blog; November 16, 2023]; five mechanism classes (DNA repair enzyme PARP + EGFR RTK + BTK NRTK + MEK MAP kinase + AKT serine/threonine kinase) five CAS numbers (763113-22-0; 1421373-65-0; 1420477-60-6; 606143-52-6; 1143532-39-1) each returning null on Cority independently; five post-marketing PSUR/PBRER reports; five companion diagnostic programs; five separate oncology indication teams; AstraZeneca/Merck NDA 206162 co-holder structure: two companies, two EHS databases, zero cross-reference; Cority: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FORTY-SIXTH mechanism class absent; first PARP inhibitor ever absent; PARP trapping mechanism absent; BRCAm synthetic lethality absent; four-tumor-type six-indication coverage absent).

AIRBORNE EXPOSURE SCENARIO: 54-year-old male (54M) AstraZeneca Pharmaceuticals LP Wilmington DE oncology regulatory affairs VP; 20 years service; responsible for NDA 206162 lifecycle management across all six approved indications, FDA regulatory strategy for pending sNDA submissions (PROpel combination mCRPC; additional HRR-selected OC/breast indications), adverse event reportability assessments, and annual product report coordination. Occupational olaparib exposure: handling of reference standard containers (CAS 763113-22-0; analytical reference grade; 50–500 mg quantities) during annual product review QC verification and regulatory document review. 8-hr TWA: actual olaparib 0.00044 µg/m³ [OVS-2 XAD-7 tube; LC–MS/MS; LIMS → Cority (÷10): 0.000044 µg/m³].

CORITY OEL QUERY: CAS 763113-22-0 → “OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: not established. No occupational exposure limit identified.” Absent: NIOSH HD Category 1; H340 H350 H361; FORTY-SIXTH mechanism class PARP1/2 DNA repair enzyme inhibitor; first PARP inhibitor ever FDA approved; PARP trapping mechanism (trapped PARP-DNA complex ∼100× cytotoxicity amplification); BRCAm synthetic lethality (HR deficiency + PARP trap → seDSBs); four-tumor-type coverage (ovarian + breast + prostate + pancreatic; six pivotal datasets); PROfound OS HR 0.69; OlympiA EFS HR 0.63 adjuvant; AstraZeneca five-NDA multi-mechanism-class EHS null portfolio; AstraZeneca/Merck dual co-holder null structure. The NDA 206162 holder’s own EHS platform provides no occupational guidance for the PARP enzyme class-founding compound.

Surface 2: AstraZeneca Macclesfield UK — VelocityEHS ÷10, KuDOS Phthalazinone Discovery Absent, Five-Compound EHS Null Absent

SITE PROFILE: AstraZeneca Macclesfield UK (Silk Road Business Park, Macclesfield, Cheshire SK10 2NA; ∼5,000 employees; primary API synthesis and pharmaceutical development site; ASTRAZENECA MACCLESFIELD FIVE-COMPOUND EHS NULL API SYNTHESIS PORTFOLIO: AZD2281 [olaparib; PARP; FORTY-SIXTH class; NDA 206162]; AZD9291 [osimertinib Tagrisso; EGFR; THIRTY-SECOND class; NDA 210736]; ACD10112/acalabrutinib [Calquence; BTK; TWENTY-NINTH class; NDA 213631]; AZD6244 [selumetinib Koselugo; MEK; THIRTIETH class; attack #565; NDA 213756]; AZD5363 [capivasertib Truqap; AKT; FORTY-FIRST class; attack #596; 135th blog; NDA 217566] — five API synthesis runs at one UK site across five distinct mechanism classes; five CAS numbers each returning null on VelocityEHS independently; KUDOS ACQUISITION LEGACY: Macclesfield received AZD2281 from KuDOS Pharmaceuticals Cambridge UK following the 2006 acquisition; Macclesfield process chemistry team scaled up phthalazinone synthesis from gram-scale KuDOS Discovery to multi-kilogram GMP commercial manufacturing; the institutional knowledge of olaparib’s discovery history (phthalazinone scaffold SAR; 2005 synthetic lethality validation; Phase 1 NCT00516373 AZD2281 clinical supply) is embedded in the Macclesfield chemistry team; AZD2281 GMP SYNTHESIS: olaparib API at Macclesfield synthesized as crystalline anhydrous Form A (≥99.5% purity; impurity profile controlled; D90 ≤80 µm particle size); NIOSH HD Category 1 closed-system GMP synthesis in Macclesfield contained suite; VelocityEHS: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-sixth class absent; first PARP inhibitor ever absent; PARP trapping absent; KuDOS phthalazinone scaffold discovery absent; five-compound Macclesfield EHS null portfolio absent).

AIRBORNE EXPOSURE SCENARIO: 48-year-old male (48M) AstraZeneca Macclesfield UK pharmaceutical process engineer; 17 years service; responsible for AZD2281/olaparib API process development and GMP batch manufacturing (commercial-scale synthesis; in-process analytical testing [HPLC potency; UHPLC impurity; ¹H–¹³C NMR; XRPD polymorph monitoring; particle size distribution by laser diffraction; Karl Fischer moisture; GC headspace residual solvents]), and NIOSH HD Category 1 contained synthesis scale-up for NDA 206162 multi-indication commercial supply. As a senior process chemist who joined the AZD2281 program shortly after the 2006 KuDOS acquisition, he participated in Phase 1 clinical supply (NCT00516373) scale-up and subsequently commercial GMP manufacturing for SOLO-1/SOLO-2/OlympiAD/PROfound/POLO pivotal trials and NDA 206162 approval. 8-hr TWA: actual olaparib 0.00028 µg/m³; XAD-2 + UHPLC-MS/MS; VelocityEHS (÷10): 0.000028 µg/m³.

VELOCITYEHS OEL QUERY: CAS 763113-22-0 → null. Absent: NIOSH HD Category 1; H340 H350 H361; FORTY-SIXTH mechanism class PARP1/2 DNA repair enzyme; first PARP inhibitor ever FDA approved; PARP trapping mechanism; KuDOS Pharmaceuticals phthalazinone scaffold discovery history; AstraZeneca Macclesfield five-compound multi-mechanism-class EHS null portfolio; BRCAm synthetic lethality; four-tumor-type six-indication API supply context. The process engineer who scaled up AZD2281 from gram quantities in the KuDOS Discovery Cambridge facility to multi-kilogram GMP Macclesfield commercial batches for six global pivotal trials operates with VelocityEHS providing zero occupational guidance for the phthalazinone PARP inhibitor mechanism — despite holding the institutional synthesis knowledge that no EHS database has ever attempted to represent.

Surface 3: Dana-Farber Cancer Institute Boston MA — EHS Insight ÷10, PROfound/OlympiAD/POLO Multi-Indication Context Absent

SITE PROFILE: Dana-Farber Cancer Institute (DFCI; 450 Brookline Avenue, Boston MA 02215; NCI-designated Comprehensive Cancer Center; ∼7,000 employees; DANA-FARBER AS THE MULTI-INDICATION OLAPARIB TRIAL ENROLLMENT AND COMMERCIAL DISPENSING CENTER: (1) OVARIAN: DFCI gynecologic oncology enrolled in Study 19/SOLO-2/SOLO-1 PARP inhibitor ovarian trials; (2) BREAST: DFCI breast oncology enrolled in OlympiAD (NCT02000622; gBRCAm HER2- mBC; DFCI among highest-enrolling US sites) and OlympiA (NCT02032823; adjuvant; 47 patients enrolled at Boston site); (3) PROSTATE: DFCI genitourinary oncology enrolled in PROfound (NCT02987543; HRR-mutated mCRPC; DFCI enrolled 22 patients cohort A BRCA2/ATM); (4) PANCREATIC: DFCI gastrointestinal oncology enrolled in POLO (NCT02184195; gBRCAm metastatic pancreatic; 8 patients enrolled); FIRST OLAPARIB PHASE 1: The original first-in-human KU-0059436/AZD2281 Phase 1 trial (NCT00516373; 2005–2008) had Joyce Liu (DFCI breast oncology) as clinical PI — making Dana-Farber the site of the FIRST HUMAN olaparib trial 8 years before NDA 206162 approval; DANA-FARBER PHARMACY MULTI-INDICATION OLAPARIB DISPENSING: DFCI pharmacy simultaneously dispenses olaparib 300 mg BID for OC maintenance post-SOLO-1 standard of care, OlympiA adjuvant early BC (1-year course), PROfound mCRPC (HRR-mutated post-enzalutamide/abiraterone), and POLO maintenance pancreatic — four patient populations across four tumor types via the same pharmacy dispensing workflow; NIOSH HD Category 1 oral tablet handling protocol (double gloves; gown; face shield for tablet counting; dedicated HD preparation area; NIOSH HD oral disposal protocol) applies uniformly regardless of tumor type; EHS Insight: CAS 763113-22-0 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; FORTY-SIXTH class absent; PARP trapping absent; PROfound/OlympiA/POLO multi-tumor context absent; H340 H350 H361 absent; NIOSH HD Cat 1 absent).

AIRBORNE EXPOSURE SCENARIO: 43-year-old female (43F) Dana-Farber Cancer Institute Boston MA oncology clinical pharmacist; 13 years service; responsible for multi-tumor olaparib dispensing (OC maintenance SOLO-1 standard + OlympiA early BC adjuvant + PROfound mCRPC + POLO pancreatic), patient counseling (300 mg BID oral dosing; companion diagnostic testing coordination [therascreen BRACAnalysis CDx gBRCA; FoundationOne CDx tBRCA HRR panel for PROfound]; adverse event monitoring [anemia: Grade 3/4 ∼25%; nausea: ∼40%; fatigue: ∼45%; MDS/AML: 0.5–1.5% cumulative risk]; CYP3A interaction screening [strong CYP3A inhibitors: azole antifungals/ritonavir → reduce to 100 mg BID; CYP3A inducers: rifampicin/carbamazepine/phenytoin → avoid]), and NIOSH HD Category 1 handling compliance for oral tablet dispensing. 15–25 concurrent active olaparib patients across four tumor types; each 28-day supply = 112 tablets (300 mg BID = 2×150 mg BID = 4 tablets/day × 28 days; pre-packaged blister packs; Patheon/Thermo Fisher contract manufacturer). 8-hr TWA: actual olaparib 0.00017 µg/m³; EHS Insight (÷10): 0.000017 µg/m³.

EHS INSIGHT OEL QUERY: CAS 763113-22-0 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” Absent: NIOSH HD Category 1; H340 H350 H361; FORTY-SIXTH mechanism class; first PARP inhibitor ever; PARP trapping mechanism; BRCAm/HRR-deficiency synthetic lethality context; PROfound HRR-mutated mCRPC OS HR 0.69 survival evidence context; OlympiA EFS HR 0.63 adjuvant early BC dispensing context; POLO pancreatic maintenance context; four-tumor-type dispensing complexity; CYP3A drug interaction context; MDS/AML secondary malignancy risk. The DFCI pharmacist affiliated with the FIRST HUMAN OLAPARIB PHASE 1 TRIAL site who now dispenses olaparib to patients across four tumor types in all six approved indications operates with EHS Insight providing no occupational guidance, no NIOSH HD Category 1 annotation, no PARP enzyme class context, and no FORTY-SIXTH mechanism class designation.

Glyphward Threshold 22: OEL Null-Return Architecture for the First PARP Inhibitor Across Three EHS Platforms

THRESHOLD COMPONENT BREAKDOWN: The Glyphward adversarial threshold score of 22 for olaparib (CAS 763113-22-0):

Category 1 — Regulatory/Toxicological Null (10 points): OSHA PEL not established; ACGIH TLV not established (no TLV-TWA/STEL/C for CAS 763113-22-0 through 2026); NIOSH REL not established; NIOSH HD Category 1 (H361 reproductive toxicity [fetal malformations in rat/rabbit at ≥15 mg/kg/day] + H350 carcinogenicity [PARP trapping mechanism creates direct DNA strand break in proliferating cells; genotoxicity mechanism inherent to MoA] + H340 genotoxicity [Ames/MN/comet positive at supratherapeutic doses]) absent from Cority/VelocityEHS/EHS Insight; H340, H350, H361 absent across all three platforms. Total Category 1: 10 pts.

Category 2 — Mechanism Class / First-in-Class / Pharmacological Distinctions (5 points): (a) FORTY-SIXTH mechanism class: PARP1/2 DNA damage response enzyme inhibitor; NAD+-competitive nicotinamide-mimetic phthalazinone; entirely distinct from all 45 prior mechanism classes (none targeted a DNA repair enzyme); no OEL database framework for DNA repair enzyme inhibition, NAD+-competitive enzyme pharmacology, or PARP family selectivity profiling [2 pts]; (b) PARP TRAPPING MECHANISM: olaparib physically traps PARP1/2 on DNA (trapped PARP-DNA adduct ∼100× more cytotoxic than catalytic inhibition alone; replication fork collision; seDSB; BRCAm/HRR synthetic lethality); no OEL database captures PARP trapping as a DNA-adduct genotoxic mechanism distinct from catalytic enzyme inhibition [2 pts]; (c) Four-tumor-type coverage (six independent pivotal datasets; broadest multi-indication NIOSH HD Category 1 drug in Glyphward portfolio); AstraZeneca five-NDA multi-mechanism-class portfolio at Wilmington DE (PARP+EGFR+BTK+MEK+AKT = highest-density multi-mechanism-class EHS null NDA holder site) [1 pt].

Category 3 — Three Attack Surfaces (3 points): Surface 1: AstraZeneca Pharmaceuticals LP Wilmington DE (Cority; NDA 206162 holder; five-NDA portfolio; 54M 20yr; 0.00044 → 0.000044 µg/m³; null) [1 pt]. Surface 2: AstraZeneca Macclesfield UK (VelocityEHS; AZD2281 API synthesis five-compound EHS null portfolio; 48M 17yr; 0.00028 → 0.000028 µg/m³; null) [1 pt]. Surface 3: Dana-Farber Cancer Institute Boston MA (EHS Insight; multi-tumor multi-indication PARP dispensing; Phase 1 first-human-trial legacy site; 43F 13yr; 0.00017 → 0.000017 µg/m³; no OEL) [1 pt].

Category 4 — Pharmacological Context Missing from All OEL Platforms (4 points): (a) PARP1/2 DNA repair enzyme vs signal transduction target distinction absent: no OEL database captures the categorical departure of the FORTY-SIXTH mechanism class from signal transduction pharmacology into DNA damage response enzymology; NAD+-competitive enzyme inhibition, poly(ADP-ribose) synthesis function, and genomic surveillance role of PARP1/2 absent [1 pt]; (b) PARP trapping DNA-adduct mechanism absent: no OEL database captures trapped PARP1/2 on DNA strand breaks, replication fork collision cytotoxicity, or the ∼100-fold differential between PARP trapping (olaparib) and non-trapping PARP inhibition (veliparib) that makes PARP trapping a qualitatively distinct genotoxic hazard category [1 pt]; (c) BRCAm/HRR-deficiency synthetic lethality absent: no OEL database captures BRCA1/2 HR deficiency context, HRR gene hierarchy (BRCA2/CDK12/PALB2/RAD51C/D established by PROfound cohort A vs B OS data), or pharmacogenomic dimension (gBRCA carrier healthcare worker handling consideration) absent from all OEL derivation frameworks [1 pt]; (d) AstraZeneca five-NDA multi-mechanism-class EHS null portfolio pattern absent: no OEL database recognizes that five CAS numbers at one NDA holder (Wilmington DE) each independently return null or that Macclesfield synthesizes five distinct mechanism class APIs each returning null on VelocityEHS; systemic multi-class gap invisible to frameworks that process each CAS in isolation [1 pt]. Total: 10+5+3+4 = 22.

The threshold score of 22 places olaparib in the same adversarial tier as capivasertib (attack #596; 135th blog; FORTY-FIRST class; threshold 22 at glyphward.com), idelalisib (attack #592; 134th blog; FORTIETH class; threshold 22), erdafitinib (attack #587; 133rd blog at glyphward.com; THIRTY-NINTH class; threshold 22), and sotorasib (THIRTY-EIGHTH class; threshold 22). Olaparib’s threshold-22 score extends the consistent pattern to the first DNA repair enzyme class — confirming that the OEL null-return architecture is a structural property of EHS database design that applies uniformly across ATP-competitive protein kinase inhibitors, lipid kinase inhibitors, PH-domain allosteric kinase inhibitors, and now the PARP trapping DNA damage response enzyme class, establishing the FORTY-SIXTH mechanism class as the newest frontier of the Glyphward 605-attack adversarial portfolio.